Brief: Arca Biopharma Announces Completion Of Enrollment In Phase 2B Aspen-Covid-19 Clinical Trial Evaluating Rnapc2 As A Potential Treatment For Patients Hospitalized With Covid-19
02/12/2021 13:40
Dec 2 (Reuters) - ARCA Biopharma Inc ABIO.O :
* ARCA BIOPHARMA ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE
2B
ASPEN-COVID-19 CLINICAL TRIAL EVALUATING RNAPC2 AS A POTENTIAL
TREATMENT FOR PATIENTS HOSPITALIZED WITH COVID-19
* ARCA BIOPHARMA INC - TOPLINE READOUT OF CLINICAL TRIAL
RESULTS
ANTICIPATED IN Q1 OF 2022
Source text for Eikon: ID:nGNX8CrxZR
Further company coverage: ABIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oruka Therapeutics
See all newsOruka falls after reporting mid-stage data for psoriasis drug
Brief: Oruka Therapeutics Announces Positive Week 28 Data For Orka-001 From The Ongoing Everlast-A Trial Showing Deepening Of Responses Without Additional Dosing
Brief: Oruka Therapeutics Appoints Todd Edwards As Chief Commercial Officer
U.S. RESEARCH ROUNDUP-Accendra Health, Celestica, Sionna Therapeutics
Oruka Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary